Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population

References

• Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, Belanger S, Abbott RK, Kim C, Choi J, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183:996–1012.e19. doi:10.1016/j.cell.2020.09.038.
   PubMed Web of Science ®Google Scholar
• Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He WT, Limbo O, Smith C, Song G, Woehl J, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020;369:956–6. doi:10.1126/science.abc7520.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111.
   PubMed Web of Science ®Google Scholar
• Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–78.
   PubMed Web of Science ®Google Scholar
• Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397:881–91.
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27:1205–11. doi:10.1038/s41591-021-01377-8.
   PubMed Web of Science ®Google Scholar
• Salazar E, Kuchipudi SV, Christensen PA, Eagar TN, Yi X, Zhao P, Jin Z, Long SW, Olsen RJ, Chen J, et al. Relationship between anti-spike protein antibody titers and SARS-CoV-2 in vitro virus neutralization in convalescent plasma. bioRxiv. 2020;2020.06.08.138990. doi:10.1101/2020.06.08.138990.
   Google Scholar
• Flaxman A, Marchevsky N, Jenkin D, Aboagye J, Aley PK, Angus BJ, Belij-Rammerstorfer S, Bibi S, Bittaye M, Cappuccini F, et al. Tolerability and immunogenicity after a late second dose or a third dose of ChAdOx1 (AZD1222) nCoV-19 (AZD1222). SSRN. 2021. https://ssrn.com/abstract=3873839 or doi:10.2139/ssrn.3873839 .
   Google Scholar
• Kristiansen PA, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K, Plotkin S, Knezevic I. WHO international standard for anti-SARS-CoV-2 immunoglobulin. Lancet. 2021;397:1347–48. doi:10.1016/S0140-6736(21)00527-4.
   PubMed Web of Science ®Google Scholar
• Resman Rus K, Korva M, Knap N, Avsic Zupanc T, Poljak M. Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay. J Clin Virol. 2021;139:104820. doi:10.1016/j.jcv.2021.104820.
   PubMed Web of Science ®Google Scholar
• Doria-Rose N, Suthar MS, Makowski M, O’Connell S, McDermott AB, Flach B, Ledgerwood JE, Mascola JR, Graham BS, Lin BC, et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for COVID-19. N Engl J Med. 2021;384:2259–61. doi:10.1056/NEJMc2103916.
   PubMed Web of Science ®Google Scholar
• Tatsis N, Fitzgerald JC, Reyes-Sandoval A, Harris-mccoy KC, Hensley SE, Zhou D, Lin S-W, Bian A, Xiang ZQ, Iparraguirre A, et al. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood. 2007 Sept 15;110(6):1916–23. doi:10.1182/blood-2007-02-062117.
   PubMed Web of Science ®Google Scholar
• Finn JD, Bassett J, Millar JB, Grinshtein N, Yang TC, Parsons R, Evelegh C, Wan Y, Parks RJ, Bramson JL, et al. Persistence of transgene expression influences CD8+ T-cell expansion and maintenance following immunization with recombinant adenovirus. J Virol. 2009 Dec;83(23):12027–36.
   PubMed Web of Science ®Google Scholar
• Penaud-Budloo M, Le Guinea C, Nowrouzi A, Toromanoff A, Cherel Y, Chenuaud P, Schmidt M, von Kalle C, Rolling F, Moullier P, et al. Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle. J Virol. 2008 Aug;82(16):7875–85. doi:10.1128/JVI.00649-08.
   PubMed Web of Science ®Google Scholar
• De Santis O, Audran R, Pothin E, Warpelin-Decrausaz L, Vallotton L, Wuerzner G, Cochet C, Estoppey D, Steiner-Monard V, Lonchampt S, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis. 2016 Mar;16(3):311–20. doi:10.1016/S1473-3099(15)00486-7.
   PubMed Web of Science ®Google Scholar
• Frenck RW Jr., Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, Perez JL, Walter EB, Senders S, Bailey R, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021 July 15;385(3):239–50. doi:10.1056/NEJMoa2107456.
   PubMed Web of Science ®Google Scholar
• Ali K, Berman G, Zhou H, Deng W, Faughnan V, Coronado-Voges M, Ding B, Dooley J, Girard B, Hillebrand W, et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. N Engl J Med. 2021 Dec 9;385(24):2241–51. doi:10.1056/NEJMoa2109522.
   PubMed Web of Science ®Google Scholar
• Menigoz K, Nathan A, Turrell G. Ethnic differences in overweight and obesity and the influence of acculturation on immigrant bodyweight: evidence from a national sample of Australian adults. BMC Public Health. 2016 Sept 5;16:932. doi:10.1186/s12889-016-3608-6.
   PubMed Web of Science ®Google Scholar
• Jethwa H, Wong R, Abraham S. Covid-19 vaccine trials: ethnic diversity and immunogenicity. Vaccine. 2021 June 16;39(27):3541–43. doi:10.1016/j.vaccine.2021.05.017.
   PubMed Web of Science ®Google Scholar
• Mathur R, Rentsch CT, Morton CE, Hulme WJ, Schultze A, MacKenna B, Eggo RM, Bhaskaran K, Wong AYS, Williamson EJ, et al. Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. Lancet. 2021 May 8;397(10286):1711–24. doi:10.1016/S0140-6736(21)00634-6.
   PubMed Web of Science ®Google Scholar
• Avnir Y, Watson CT, Glanville J, Peterson EC, Tallarico AS, Bennett AS, Qin K, Fu Y, Huang C-Y, Beigel JH, et al. IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with IGHV utilization shifts and varies by ethnicity. Sci Rep. 2016 Feb 16;6:20842. doi:10.1038/srep20842.
   PubMed Web of Science ®Google Scholar